These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 20410221)

  • 1. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
    Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes.
    Erotokritou-Mulligan I; Bassett EE; Bartlett C; Cowan D; McHugh C; Seah R; Curtis B; Wells V; Harrison K; Sönksen PH; Holt RI;
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2760-3. PubMed ID: 18413420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
    Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.
    Ehrnborg C; Lange KH; Dall R; Christiansen JS; Lundberg PA; Baxter RC; Boroujerdi MA; Bengtsson BA; Healey ML; Pentecost C; Longobardi S; Napoli R; Rosén T;
    J Clin Endocrinol Metab; 2003 Jan; 88(1):394-401. PubMed ID: 12519882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
    Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
    Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
    Kniess A; Ziegler E; Thieme D; Müller RK
    J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes.
    Nelson AE; Howe CJ; Nguyen TV; Leung KC; Trout GJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4424-32. PubMed ID: 16912136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ethnicity on IGF-I and procollagen III peptide (P-III-P) in elite athletes and its effect on the ability to detect GH abuse.
    Erotokritou-Mulligan I; Bassett EE; Cowan DA; Bartlett C; McHugh C; Sönksen PH; Holt RI;
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):161-8. PubMed ID: 18616716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting.
    Healy ML; Dall R; Gibney J; Bassett E; Ehrnborg C; Pentecost C; Rosen T; Cittadini A; Baxter RC; Sönksen PH
    J Clin Endocrinol Metab; 2005 Feb; 90(2):641-9. PubMed ID: 15546908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
    Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
    Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
    J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic factors influencing the GH system: Implications for the detection of GH doping in sport.
    Nelson AE; Ho KK
    Growth Horm IGF Res; 2009 Aug; 19(4):327-32. PubMed ID: 19481485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
    Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
    J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant growth hormone misuse: insulin-like growth factor I and procollagen type III peptide.
    Abellan R; Ventura R; Pichini S; Di Giovannandrea R; Bellver M; Olive R; Pacifici R; Pascual JA; Zuccaro P; Segura J
    Int J Sports Med; 2006 Dec; 27(12):976-83. PubMed ID: 16612742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
    Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
    Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes.
    Holt RI; Erotokritou-Mulligan I; McHugh C; Bassett EE; Bartlett C; Fityan A; Bacon JL; Cowan DA; Sönksen PH
    Eur J Endocrinol; 2010 Jul; 163(1):45-54. PubMed ID: 20421332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of two weeks of recombinant growth hormone administration on the response of IGF-I and N-terminal pro-peptide of collagen type III (P-III-NP) during a single bout of high resistance exercise in resistance trained young men.
    Velloso CP; Aperghis M; Godfrey R; Blazevich AJ; Bartlett C; Cowan D; Holt RI; Bouloux P; Harridge SD; Goldspink G
    Growth Horm IGF Res; 2013 Jun; 23(3):76-80. PubMed ID: 23433656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.